Thyrotoxic periodic paralysis: clinical challenges

Area of Science:

• Endocrinology
• Genetics
• Neurology

Background:

• Thyrotoxic periodic paralysis (TPP) is a rare neuromuscular disorder characterized by episodic hypokalemia and paralysis.
• It is predominantly observed in Asian men and is secondary to thyrotoxicosis, often with subtle hyperthyroidism.
• Triggers include high-carbohydrate meals, exercise, stress, and steroid use, complicating early diagnosis.

Purpose of the Study:

• To elucidate the pathogenesis of thyrotoxic periodic paralysis.
• To highlight the role of genetic mutations in the Kir2.6 channel.
• To emphasize diagnostic criteria and management strategies for TPP.

Main Methods:

• Review of existing literature on TPP.
• Analysis of genetic factors, specifically Kir2.6 channel mutations.
• Examination of biochemical and electrocardiographic findings in TPP patients.

Main Results:

• Evidence suggests loss-of-function mutations in the Kir2.6 channel contribute to TPP pathogenesis.
• Increased Na(+)/K(+) ATPase activity may exacerbate hypokalemia.
• Characteristic findings include biochemical hyperthyroidism, normal urinary potassium excretion, and specific ECG changes.

Conclusions:

• Genetic mutations in the Kir2.6 channel play a significant role in TPP.
• Early diagnosis is critical, supported by biochemical and ECG findings.
• Management involves potassium supplements and nonselective beta-blockers, with careful monitoring for rebound hyperkalemia.